According to a recent LinkedIn post from Truveta, the company is highlighting how recruitment delays remain a major risk in clinical development, particularly in rare disease trials. The post describes a Phase 2 study for a rare blood disorder in which enrollment slowed because a key patient subgroup was hard to locate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that by using daily refreshed electronic health record data, including lab and transfusion history, Truveta applied trial inclusion criteria to identify health systems currently treating eligible patients. This approach reportedly supported the launch of a new clinical trial site and also informed the design of an external control arm for a future Phase 3 study.
For investors, the LinkedIn content points to a use case where Truveta’s data platform may help accelerate trial timelines and improve site selection, areas that are increasingly important to biopharma sponsors. If such capabilities gain broader adoption, they could strengthen Truveta’s position in real‑world data and clinical trial enablement, potentially supporting revenue growth through deeper partnerships with life sciences companies.